Rheumatoid arthritis treatment has advanced significantly, giving patients more ways to manage inflammation, protect their joints and maintain their quality of life. Conventional disease-modifying medications, biologic therapies and targeted synthetic drugs can be highly effective, but some people continue to experience active disease after trying multiple options.
SetPoint therapy introduces a different approach. Instead of delivering another medication, it uses a small implanted device to stimulate the vagus nerve, which plays a role in communication between the nervous system and the immune system. For patients learning about evolving treatments through Pacific Arthritis Care Center in Los Angeles and Santa Monica, understanding how this technology works can help support informed conversations with a rheumatologist.
What Is SetPoint Therapy?
SetPoint therapy is a form of neuroimmune modulation. This means it uses the nervous system to influence immune activity and help regulate inflammation.
The SetPoint System includes a small rechargeable device that is surgically implanted around the vagus nerve in the neck. Once activated, the device delivers a controlled electrical signal for approximately one minute each day.
The treatment is intended for certain adults with moderately to severely active rheumatoid arthritis who have not responded adequately to, have stopped responding to or cannot tolerate biologic or targeted synthetic disease-modifying medications.
It is important to distinguish SetPoint therapy from general treatments for joint pain. It is not designed for every type of arthritis, fibromyalgia, osteoarthritis or occasional musculoskeletal discomfort.
How the Vagus Nerve Influences Inflammation
Rheumatoid arthritis is an autoimmune disease in which the immune system mistakenly attacks the tissues lining the joints. This can lead to swelling, tenderness, stiffness, fatigue and progressive joint damage.
Many rheumatoid arthritis medications work by blocking specific inflammatory chemicals or immune pathways. SetPoint therapy addresses inflammation differently by targeting the inflammatory reflex.
The inflammatory reflex is a natural pathway through which the nervous system helps monitor and regulate immune activity. The vagus nerve is a major part of this communication network. When it is stimulated in a controlled manner, it may help reduce the production of certain inflammatory proteins associated with rheumatoid arthritis.
This does not mean that the nervous system is the sole cause of rheumatoid arthritis. Instead, the treatment is based on the understanding that the nervous and immune systems continuously communicate with one another.
How the SetPoint System Works
The SetPoint device is placed around the left vagus nerve during an outpatient surgical procedure. After the implantation site has had time to heal, the system is activated and programmed.
The device automatically delivers a short daily stimulation session. Patients do not have to manually start treatment each day. Because the implant is rechargeable, it must periodically be charged using an external device worn around the neck.
Follow-up remains an important part of care. A rheumatologist must continue to monitor joint symptoms, inflammation and overall disease activity. Device settings may also be adjusted based on comfort and clinical response.
SetPoint therapy is different from consumer wellness products that claim to stimulate the vagus nerve through the skin or ear. It is an implanted prescription device that requires surgical placement and ongoing medical supervision.
Who May Be Considered for Treatment?
SetPoint therapy may be considered when rheumatoid arthritis remains moderately or severely active despite previous treatment with advanced medications.
Before recommending further evaluation, a rheumatologist must determine whether symptoms are being caused by active inflammation. Persistent pain does not always mean that rheumatoid arthritis is uncontrolled. Joint discomfort may also result from osteoarthritis, tendon injuries, nerve problems, fibromyalgia or permanent damage from earlier inflammation.
A complete assessment may include a physical examination, blood tests, medication history and imaging. Musculoskeletal ultrasound may be used to identify inflammation within a joint or surrounding soft tissue. This can help distinguish active rheumatoid arthritis from other sources of pain or swelling.
Patients should provide a complete list of medications they have tried, including treatments that were ineffective, caused side effects or initially worked before losing effectiveness.
Does It Replace Rheumatoid Arthritis Medication?
Although SetPoint therapy does not release medication into the body, it may not eliminate the need for all rheumatoid arthritis drugs.
Some patients may continue taking a conventional disease-modifying medication as part of their treatment plan. Medication decisions depend on disease activity, previous responses, side effects and overall health.
Patients should never stop biologic medications, JAK inhibitors or other prescribed treatments without guidance from a rheumatologist. Changing treatment without medical supervision could allow inflammation to return and increase the risk of joint damage.
Risks and Practical Considerations
Because SetPoint therapy requires implantation, patients must consider both device-related and surgical risks. These may include infection, bleeding, discomfort, scarring or temporary voice changes associated with operating near the vagus nerve.
Patients should also ask how often the device must be charged, how treatment response will be measured and whether the implant could affect future imaging or medical procedures.
Insurance coverage and availability may vary. Authorization may be required, and access may depend on whether trained surgical and rheumatology teams are available in the patient’s area.
Some follow-up discussions may be suitable for telemedicine appointments, while physical examinations, laboratory testing and device-related evaluations may still need to be completed in person.
The Role of Research in New Rheumatology Treatments
SetPoint therapy reflects years of research into the relationship between the brain, nervous system and immune response. Early findings were followed by pilot studies and controlled clinical trials designed to evaluate safety and effectiveness.
Research and clinical trials are essential for determining which treatments provide meaningful benefit, which patients are most likely to respond and what risks must be considered.
Even after a treatment becomes available, continued research helps clinicians understand long-term outcomes and how the therapy compares with established options.
Discussing SetPoint Therapy With a Rheumatologist
Patients who are interested in SetPoint therapy should be prepared to discuss their complete treatment history, current symptoms and daily limitations. Helpful details may include how long morning stiffness lasts, which joints are swollen and how symptoms affect work, sleep, exercise or routine activities.
It is also important to ask about the implantation process, recovery, device charging, follow-up visits, medication use and potential side effects.
Pacific Arthritis Care Center serves patients throughout Los Angeles, Santa Monica and the surrounding communities who are seeking a better understanding of rheumatoid arthritis and emerging treatment approaches. SetPoint therapy is not appropriate for every patient, but for selected adults whose disease remains active after advanced medications, it may provide another option within a carefully monitored rheumatology plan.
Sources
Tesser, J. R. P., Crowley, A. R., Box, E. J., et al. (2026). Vagus nerve-mediated neuroimmune modulation for rheumatoid arthritis: A pivotal randomized controlled trial. Nature Medicine.
Genovese, M. C., Gaylis, N. B., Sikes, D., et al. (2020). Safety and efficacy of neurostimulation with a miniaturised vagus nerve stimulation device in patients with multidrug-refractory rheumatoid arthritis. The Lancet Rheumatology.
Peterson, D., Van Poppel, M., Boling, W., et al. (2024). Clinical safety and feasibility of a novel implantable neuroimmune modulation device for the treatment of rheumatoid arthritis. Bioelectronic Medicine.
